The MATRIX study: evaluating the data in older adults.

Area of Science:

• Gerontology
• Urology
• Pharmacology

Background:

• The MATRIX study assessed transdermal oxybutynin delivery system (OXY-TDS) for overactive bladder (OAB) in community-dwelling older adults.
• The study population (n=699, aged ≥75 years) exhibited characteristics common in long-term care settings, including comorbidities and a history of OAB.

Purpose of the Study:

• To evaluate the safety and efficacy of transdermal oxybutynin (OXY-TDS) for managing OAB in a community-dwelling older adult population.
• To assess the impact of OXY-TDS on OAB symptoms and QOL in elderly individuals.
• To determine the tolerability and adverse event profile of OXY-TDS in this demographic.

Main Methods:

• The MATRIX study enrolled older adults with OAB residing in community settings.
• A significant proportion of participants (699 patients) were aged 75 years or older, with many having comorbid conditions and a history of OAB.
• Data on OAB symptom improvement, QOL, and adverse events were collected and analyzed.

Main Results:

• Transdermal oxybutynin (OXY-TDS) demonstrated a favorable safety profile in older adults with OAB.
• Adverse events were predominantly minor and local, with skin irritation being the most common.
• The OXY-TDS formulation led to significant improvements in OAB symptoms and enhanced patient QOL.

Conclusions:

• Transdermal oxybutynin is a safe and effective treatment option for managing OAB in the elderly population.
• The transdermal route offers a potentially advantageous delivery method for oxybutynin in older adults, minimizing systemic exposure.
• OXY-TDS is a viable therapeutic choice for older adults with OAB, even those with characteristics similar to long-term care residents.